AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
AngioDynamics, Inc. filed a current report to furnish its financial results for the fiscal first quarter ended August 31, 2025. The company issued a press release with these results, attached as Exhibit 99.1, and also provided investor presentation slides discussing the quarter as Exhibit 99.2.
The company emphasizes that these materials are being furnished rather than filed, which limits certain securities law liabilities and controls how they are incorporated into other SEC documents. It also includes extensive forward-looking statement language, highlighting risks such as the impact of COVID-19, regulatory actions, competition, product development, litigation, economic conditions, and other factors referenced in its latest annual report.
AngioDynamics (ANGO) requests shareholder votes at its Annual Meeting on November 10, 2025, including election of two Class I directors, ratification of Deloitte & Touche LLP as auditor and an advisory "Say-on-Pay" vote. Shareholders of record as of September 18, 2025 (41,076,119 shares) may vote in person or virtually at www.virtualshareholdermeeting.com/ANGO2025. The Board describes its enterprise risk oversight process, delegating specific risks to committees and noting the Audit Committee met eight times and includes an audit committee financial expert. CEO compensation was largely performance-based (67% target) and the CEO-to-median employee pay ratio is approximately 44:1. The proxy discloses director retainer and equity grant practices, Compensation Committee use of Meridian for benchmarking, and change-in-control and severance arrangements for executives.
Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO). The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 1,527,815 shares. The stake is based on 40,633,885 shares outstanding as of May 31, 2025, per the issuer's 10-K. The Reporting Persons state the holdings were acquired in the ordinary course of business and not to influence control of the company. The Master Fund is the direct holder while Armistice exercises voting and investment authority under an investment management agreement.
Divisadero Street Capital and related entities report ownership of material stakes in AngioDynamics common stock. The filing shows Divisadero Street Capital Management, LP and affiliated entities report beneficial ownership of 3,395,430 shares, representing 8.4% of the class, while Divisadero Street Partners, L.P. and its GP report 3,054,469 shares (approximately 7.5%). The reported positions are held with shared voting and dispositive power only; no reporting person asserts sole voting or sole dispositive power.
The filing states that all reported securities are directly owned by advisory clients of Divisadero Street Capital Management, LP and that each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest. The filing includes a joint filing agreement and a control-person identification exhibit.
AngioDynamics, Inc. (NASDAQ: ANGO) filed a Form 8-K on July 15, 2025 to furnish—rather than file—materials related to its fiscal fourth-quarter and full-year results ended May 31, 2025.
- Item 2.02: The company issued a press release (Exhibit 99.1) announcing its Q4 and FY 2025 financial performance.
- Item 7.01: Investor presentation slides (Exhibit 99.2) discussing the same period were also provided.
- Both exhibits are expressly excluded from Exchange Act Section 18 liability and will not be incorporated into future Securities Act or Exchange Act filings unless specifically referenced.
- No quantitative results, guidance, or commentary appear in the 8-K text itself; investors must review the furnished exhibits for details.
The filing contains standard forward-looking-statement disclaimers and lists common risk factors that could cause actual results to differ.